Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

(2014) M. Bots et al.   BLOOD

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Cutting Edge: Chromatin Remodeling as a Molecular Basis for the Enhanced Functionality of Memory CD8 T Cells

(2014) J. K. Northrop et al.   JOURNAL OF IMMUNOLOGY

The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies

(2014) K. L. Rice et al.   JOURNAL OF INTERNAL MEDICINE

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

(2014) I-N Hsieh et al.   Cell Death & Disease

Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

(2014) Maj-Linda Selenica et al.   Alzheimers Research & Therapy

Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies

(2013) David J. Irwin et al.   AMERICAN JOURNAL OF PATHOLOGY

Spinal muscular atrophy: An update on therapeutic progress

(2013) Joonbae Seo et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity

(2013) Abhijit Saha et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of a small molecular compound simultaneously targeting RXR and HADC: Design, synthesis, molecular docking and bioassay

(2013) Guo-Liang Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Dual-acting histone deacetylase-topoisomerase I inhibitors

(2013) William Guerrant et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

(2013) S. R. Daigle et al.   BLOOD

Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function

(2013) M. R. Heideman et al.   BLOOD

Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice

(2013) O. M. Dovey et al.   BLOOD

A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance

(2013) F. Santoro et al.   BLOOD

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth

(2013) M Kaliszczak et al.   BRITISH JOURNAL OF CANCER

A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies

(2013) Gert J. Ossenkoppele et al.   BRITISH JOURNAL OF HAEMATOLOGY

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

(2013) A. C. West et al.   CANCER RESEARCH

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors

(2013) M New et al.   CELL DEATH AND DIFFERENTIATION

A Chimeric SERM-Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy

(2013) Hitisha K. Patel et al.   ChemMedChem

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials

(2013) Tianzhu Qiu et al.   Future Oncology

Genetic syndromes caused by mutations in epigenetic genes

(2013) María Berdasco et al.   HUMAN GENETICS

Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance

(2013) Casey Cook et al.   HUMAN MOLECULAR GENETICS

Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects

(2013) Santosh Vishwakarma et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Histone Deacetylase 7 Promotes Toll-like Receptor 4-dependent Proinflammatory Gene Expression in Macrophages

(2013) Melanie R. Shakespear et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone Deacetylase Inhibition Promotes Osteoblast Maturation by Altering the Histone H4 Epigenome and Reduces Akt Phosphorylation

(2013) Amel Dudakovic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity

(2013) Berkley E. Gryder et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment

(2013) Jhih-Bin Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors

(2013) David E. Olson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer’s Disease

(2013) Chao-Wu Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

(2013) J Minami et al.   LEUKEMIA

Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

(2013) A. Newbold et al.   MOLECULAR CANCER THERAPEUTICS

Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

(2013) J. Wang et al.   MOLECULAR CANCER THERAPEUTICS

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

(2013) Claudia Simões-Pires et al.   Molecular Neurodegeneration

HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy

(2013) Byram W Bridle et al.   MOLECULAR THERAPY

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

(2013) Mercedes Lobera et al.   Nature Chemical Biology

Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction

(2013) Lihong Shi et al.   NATURE MEDICINE

Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability

(2013) Jeanine Jochems et al.   NEUROPSYCHOPHARMACOLOGY

Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma

(2013) Christina E. Wells et al.   PLoS One

A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests

(2013) Frederick A. Schroeder et al.   PLoS One

HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner

(2013) M. Malvaez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of a histone deacetylase 6 inhibitor and its biological effects

(2013) J.-H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Role of the CoREST/REST Repressor Complex in Herpes Simplex Virus 1 Productive Infection and in Latency

(2013) Guoying Zhou et al.   Viruses-Basel

HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

(2013) J E Bolden et al.   Cell Death & Disease

Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance

(2013) D Dupéré-Richer et al.   Cell Death & Disease

Development of a Chimeric c-Src Kinase and HDAC Inhibitor

(2013) Kristin S. Ko et al.   ACS Medicinal Chemistry Letters

HDAC7 Is a Repressor of Myeloid Genes Whose Downregulation Is Required for Transdifferentiation of Pre-B Cells into Macrophages

(2013) Bruna Barneda-Zahonero et al.   PLoS Genetics

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

(2013) Hanne Fredly et al.   Clinical Epigenetics

Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs

(2013) Melissa D. Cantley et al.   INFLAMMOPHARMACOLOGY

HDAC inhibitor therapy in autoimmunity and transplantation

(2012) Wayne W Hancock et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Histone/protein deacetylases and T-cell immune responses

(2012) T. Akimova et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential

(2012) W.-J. Shia et al.   BLOOD

Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

(2012) Xinwei Zhang et al.   CANCER CELL

Chromatin Remodeling Underlies the Senescence-Associated Secretory Phenotype of Tumor Stromal Fibroblasts That Supports Cancer Progression

(2012) E. Pazolli et al.   CANCER RESEARCH

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

(2012) C. Qian et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma

(2012) Donna M. Weber et al.   Clinical Lymphoma Myeloma & Leukemia

Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy

(2012) T. Ai et al.   CURRENT MEDICINAL CHEMISTRY

Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease

(2012) Praveer Gupta et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease

(2012) Nambirajan Govindarajan et al.   EMBO Molecular Medicine

Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor

(2012) Dominica Willmann et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in Tamoxifen-Resistant MCF-7 Breast Cancer Cells

(2012) Young Ju Lee et al.   International Journal of Medical Sciences

Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia

(2012) Elisabetta Soragni et al.   JOURNAL OF CHILD NEUROLOGY

Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

(2012) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

(2012) Winnie Yeo et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries

(2012) Takayoshi Suzuki et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors

(2012) William Guerrant et al.   JOURNAL OF MEDICINAL CHEMISTRY

An Essential Role for Histone Deacetylase 4 in Synaptic Plasticity and Memory Formation

(2012) M.-S. Kim et al.   JOURNAL OF NEUROSCIENCE

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL

(2012) M Leiva et al.   LEUKEMIA

HDAC inhibitor-based therapies: Can we interpret the code?

(2012) Maria New et al.   Molecular Oncology

Trials with ‘epigenetic’ drugs: An update

(2012) Angela Nebbioso et al.   Molecular Oncology

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

An epigenetic blockade of cognitive functions in the neurodegenerating brain

(2012) Johannes Gräff et al.   NATURE

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

(2012) Tino Schenk et al.   NATURE MEDICINE

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease

(2012) Haiqun Jia et al.   NEUROBIOLOGY OF DISEASE

Targeting Epigenetic Readers in Cancer

(2012) Mark A. Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Studies of YK-4-272, an Inhibitor of Class II Histone Deacetylases by Disruption of Nucleocytoplasmic Shuttling

(2012) Hye-Sik Kong et al.   PHARMACEUTICAL RESEARCH

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

(2012) Li Shen et al.   PLoS One

Loss of Deacetylation Activity of Hdac6 Affects Emotional Behavior in Mice

(2012) Masahide Fukada et al.   PLoS One

Cell Cycle Regulation by the PRMT6 Arginine Methyltransferase through Repression of Cyclin-Dependent Kinase Inhibitors

(2012) Markus A. Kleinschmidt et al.   PLoS One

Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors

(2012) H. S. Bandukwala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death

(2012) N. Gammoh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors

(2012) Wenyu Yu et al.   Nature Communications

Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

(2012) Geneviève P Delcuve et al.   Clinical Epigenetics

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

(2012) Li Shen et al.   OncoImmunology

Differential regulation of the SMN2 gene by individual HDAC proteins

(2011) Matthew C. Evans et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Revisiting the differentiation paradigm in acute promyelocytic leukemia

(2011) J. Ablain et al.   BLOOD

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents

(2011) S. K. Ghosh et al.   BLOOD

Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines

(2011) Indra Sari Kusuma Harahap et al.   BRAIN & DEVELOPMENT

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

(2011) Zhi-Qiang Ning et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming

(2011) B. E. Schwartz et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

(2011) T. Nguyen et al.   CLINICAL CANCER RESEARCH

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

(2011) K Ted Thurn et al.   Future Oncology

Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice

(2011) Deborah Y. Kwon et al.   HUMAN MOLECULAR GENETICS

HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation

(2011) Matthew J Sweet et al.   IMMUNOLOGY AND CELL BIOLOGY

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

(2011) Karen M VanderMolen et al.   JOURNAL OF ANTIBIOTICS

Efficacy of Antidepressants for Late-Life Depression

(2011) Enrico Tedeschini et al.   JOURNAL OF CLINICAL PSYCHIATRY

Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia

(2011) D J P M Stumpel et al.   LEUKEMIA

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

(2011) Wenjuan Yu et al.   LEUKEMIA RESEARCH

Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells

(2011) E. F. de Zoeten et al.   MOLECULAR AND CELLULAR BIOLOGY

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

(2011) G. Dasmahapatra et al.   MOLECULAR CANCER THERAPEUTICS

Unknown

(2011) Leo Joosten et al.   MOLECULAR MEDICINE

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

(2011) Thomas Robert et al.   NATURE

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes

(2011) Maria N Navarro et al.   NATURE IMMUNOLOGY

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

(2011) Chiranjeevi Sandi et al.   NEUROBIOLOGY OF DISEASE

Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease

(2011) Anna Bobrowska et al.   PLoS One

Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells

(2011) Luca A. Petruccelli et al.   PLoS One

Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease

(2011) J. Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone deacetylases as regulators of inflammation and immunity

(2011) Melanie R. Shakespear et al.   TRENDS IN IMMUNOLOGY

The acetylation of tau inhibits its function and promotes pathological tau aggregation

(2011) Todd J. Cohen et al.   Nature Communications

Haploinsufficiency of HDAC4 Causes Brachydactyly Mental Retardation Syndrome, with Brachydactyly Type E, Developmental Delays, and Behavioral Problems

(2010) Stephen R. Williams et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma

(2010) Yuan-Ling Liu et al.   Autophagy

Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids

(2010) Marc Lamblin et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound  -phenylethyl isothiocyanate

(2010) Y. Hu et al.   BLOOD

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability

(2010) Srividya Bhaskara et al.   CANCER CELL

Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions

(2010) Mareike Schmudde et al.   CANCER LETTERS

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

(2010) Cheng-Jung Lai et al.   CANCER RESEARCH

Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage

(2010) Chiara Conti et al.   CANCER RESEARCH

Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production

(2010) Kevin Bonham et al.   FEBS Journal

Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression

(2010) T. Yamaguchi et al.   GENES & DEVELOPMENT

Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat

(2010) Ben P. Martin et al.   INTERNATIONAL JOURNAL OF CANCER

Conditional Deletion of Histone Deacetylase 1 in T Cells Leads to Enhanced Airway Inflammation and Increased Th2 Cytokine Production

(2010) R. Grausenburger et al.   JOURNAL OF IMMUNOLOGY

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

(2010) Kyle V. Butler et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells

(2010) W Song et al.   LEUKEMIA

Suppression of inflammation by a synthetic histone mimic

(2010) Edwige Nicodeme et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy

(2010) Sang-Won Min et al.   NEURON

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

(2010) G M Marshall et al.   ONCOGENE

Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor

(2010) Sushant K. Kachhap et al.   PLoS One

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

(2010) M. Namdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenetic regulation of CD8+ T-lymphocyte mediated suppression of HIV-1 replication

(2010) Kevin O. Saunders et al.   VIROLOGY

Histone deacetylase inhibitors and HIV latency

(2010) David M Margolis   Current Opinion in HIV and AIDS

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

(2009) Nancie M Archin et al.   AIDS

Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors

(2009) Pierre Tessier et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

CBF  is critical for AML1-ETO and TEL-AML1 activity

(2009) L. Roudaia et al.   BLOOD

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

(2009) L. Ellis et al.   BLOOD

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation

(2009) Hyunkyung Jeong et al.   CELL

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitors In Inflammatory Disease

(2009) Maria Halili et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Inhibition of HDAC9 Increases T Regulatory Cell Function and Prevents Colitis in Mice

(2009) Edwin F. de Zoeten et al.   GASTROENTEROLOGY

A phosphorylation-acetylation switch regulates STAT1 signaling

(2009) O. H. Kramer et al.   GENES & DEVELOPMENT

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

(2009) D. Ritchie et al.   HAEMATOLOGICA

Histone Deacetylases 1 and 2 Form a Developmental Switch That Controls Excitatory Synapse Maturation and Function

(2009) M. W. Akhtar et al.   JOURNAL OF NEUROSCIENCE

HDAC2 negatively regulates memory formation and synaptic plasticity

(2009) Ji-Song Guan et al.   NATURE

Histone deacetylases and the immunological network: implications in cancer and inflammation

(2009) A Villagra et al.   ONCOGENE

Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development

(2009) R. L. Montgomery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

Multiple roles of HDAC inhibition in neurodegenerative conditions

(2009) De-Maw Chuang et al.   TRENDS IN NEUROSCIENCES

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

(2008) K. F. Whitecross et al.   BLOOD

Targeting tumor angiogenesis with histone deacetylase inhibitors

(2008) Leigh Ellis et al.   CANCER LETTERS

Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors

(2008) A. F. Setiadi et al.   CANCER RESEARCH

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

HDAC4 inhibits cell-cycle progression and protects neurons from cell death

(2008) Nazanin Majdzadeh et al.   Developmental Neurobiology

Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma

(2008) Takashi Murakami et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pulse Inhibition of Histone Deacetylases Induces Complete Resistance to Oxidative Death in Cortical Neurons without Toxicity and Reveals a Role for Cytoplasmic p21waf1/cip1 in Cell Cycle-Independent Neuroprotection

(2008) B. Langley et al.   JOURNAL OF NEUROSCIENCE

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

(2008) S Balasubramanian et al.   LEUKEMIA

Histone Deacetylase 5 Acquires Calcium/Calmodulin-Dependent Kinase II Responsiveness by Oligomerization with Histone Deacetylase 4

(2008) J. Backs et al.   MOLECULAR AND CELLULAR BIOLOGY

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

(2008) A. Newbold et al.   MOLECULAR CANCER THERAPEUTICS

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

(2008) Alejandro Villagra et al.   NATURE IMMUNOLOGY

Deregulation of HDAC1 by p25/Cdk5 in Neurotoxicity

(2008) Dohoon Kim et al.   NEURON

HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model

(2008) Myriam Rai et al.   PLoS One

Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist

(2008) L. E. Tavera-Mendoza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Class IIA HDACs in the regulation of neurodegeneration

(2007) Nazanin Majdzadeh   Frontiers in Bioscience-Landmark